Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2022 08:30 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Announces Positive Results from the Ongoing STS101 ASCEND Phase 3 Open-label, Long-term Safety Trial

STS101 demonstrated a favorable safety and tolerability profile, consistent with clinical experience to dateOver 8,000 migraine attacks treated with more than 10,000 doses of STS101; of which, over...
September 06, 2022 08:02 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
August 09, 2022 16:05 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects - - On track to announce SUMMIT trial topline results in Q4 2022 - - Completed...
August 02, 2022 08:00 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

- More than 1,400 subjects randomized -- Satsuma expects to announce topline SUMMIT trial results in Q4 2022 - SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Satsuma...
June 09, 2022 07:00 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society’s 64th Annual Scientific Meeting

SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
June 07, 2022 16:05 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
May 11, 2022 16:05 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...
May 10, 2022 16:05 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 - - New Drug Application (NDA) submission anticipated in Q1 2023 - - $80.6 million in...
March 15, 2022 16:03 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 - - $95.8 million in cash, cash equivalents and marketable securities as of...
March 03, 2022 16:05 ET | Source: Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)...